Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer

In Vivo

Volumn 28, Issue 3, 2014, Pages 287-292

  Gezer, Ugur ^a   Holdenrieder, Stefan ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Circulating nucleosomes; Colorectal cancer; Epigenetic alterations; Histone modifications; Review; Serum

Indexed keywords

HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; NUCLEOSOME; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CHROMATIN STRUCTURE; COLORECTAL CANCER; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; NUCLEOSOME; ONCOGENE; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION INITIATION; BLOOD; COLORECTAL NEOPLASMS; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHYLATION; PROGNOSIS;

COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; HISTONES; HUMANS; METHYLATION; NUCLEOSOMES; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84918564270     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Gurzu S, Szentirmay Z and Jung I: Molecular classification of colorectal cancer: A dream that can become a reality. Rom J Morphol Embryol 54: 241-245, 2013.
2. Mallinson EK, Newton KF, Bowen J, Lalloo F, Clancy T, Hill J and Evans DG: The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut 59: 378-382, 2010.
3. Hayat MJ, Howlader N, Reichman ME and Edwards BK: Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37, 2007.
4. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259, 2006.
5. Worthley DL and Leggett BA: Colorectal cancer: Molecular features and clinical opportunities. Clin Biochem Rev 31: 31-38, 2010.
6. Colussi D, Brandi G, Bazzoli F and Ricciardiello L: Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int J Mol Sci 14: 16365-16385, 2013.
7. Rawson JB and Bapat B: Epigenetic biomarkers in colorectal cancer diagnostics. Expert Rev Mol Diagn 12: 499-509, 2012.
8. Choong MK and Tsafnat G: Genetic and epigenetic biomarkers of colorectal cancer. Clin Gastroenterol Hepatol 10: 9-15, 2012.
9. Taby R and Issa, JP: Cancer epigenetics. CA Cancer J Clin 60: 376-392, 2010.
10. Kurdistani SK: Histone modifications in cancer biology and prognosis. Prog Drug Res 67: 91-106, 2011.
11. Hassler MR and Egger G: Epigenomics of cancer-emerging new concepts. Biochimie 94: 2219-2230, 2012.
12. Waldmann T and Schneider R: Targeting histone modifications - epigenetics in cancer. Curr Opin Cell Biol 25: 184-189, 2013.
13. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S and Longacre M: Cancer development, progression, and therapy: An epigenetic overview. Int J Mol Sci 14: 21087-21113, 2013.
14. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
15. Baylin SB and Jones PA: A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11: 726-734, 2011.
16. Pedersen MT and Helin K: Histone demethylases in development and disease. Trends Cell Biol 20: 662-671, 2010.
17. Kouzarides T: SnapShot: Histone-modifying enzymes. Cell 128: 802, 2007.
18. Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, Lu Z, Ye Z, Zhu Q, Wysocka J, Ye Y, Khochbin S, Ren B and Zhao Y: Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146: 1016-1028, 2011.
19. Bannister AJ and Kouzarides T: Regulation of chromatin by histone modifications. Cell Res 21: 381-395, 2011.
20. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
21. Schneider R and Grosschedl R: Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev 21: 3027-3043, 2007.
22. Turner BM: Histone acetylation and an epigenetic code. Bioessays 22: 836-845, 2000.
23. Munshi A, Shafi G, Aliya N and Jyothy A: Histone modifications dictate specific biological readouts. J Genet Genomics 36: 75-88, 2009.
24. Zhou VW, Goren A and Bernstein BE: Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12: 7-18, 2011.
25. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, Ku M, Durham T, Kellis M and Bernstein BE: Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49, 2011.
26. Butler JS, Koutelou E, Schibler AC and Dent SY: Histonemodifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics 4: 163-177, 2012.
27. Spiegel S, Milstien S and Grant S: Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551, 2012.
28. Berry WL and Janknecht R: KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73: 2936-2942, 2013.
29. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
30. Chervona Y and Costa M: Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res 2: 589-597, 2012.
31. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T and Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
32. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH and Smoot D: Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 54: 2109-2117, 2009.
33. Nakazawa T, Kondo T, Ma D Niu D, Mochizuki K, Kawasaki T, Yamane T, Iino H, Fujii H and Katoh R: Global histone modification of histone H3 in colorectal cancer and its precursor lesion. Hum Pathol 43: 834-842, 2012.
34. Stypula-Cyrus Y, Damania D, Kunte DP, Cruz MD, Subramanian H, Roy HK and Backman V: HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 8: e64600, 2013.
35. Fu L, Chen L, Yang J, Ye T, Chen Y and Fang J: HIF-1α-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis 33: 1664-1673, 2012.
36. Yokoyama Y, Hieda M, Nishioka Y, Matsumoto A, Higashi S, Kimura H, Yamamoto H, Mori M, Matsuura S and Matsuura N: Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci 104: 889-895, 2013.
37. Tamagawa H, Oshima T, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Masuda M, Imada T and Miyagi Y: The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 27: 637-642, 2012.
38. Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Yukawa N, Rino Y, Masuda M and Miyagi Y: Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 39: 655-661, 2013.
39. Nakazawa T, Kondo T, Ma D, Niu D, Mochizuki K, Kawasaki T, Yamane T, Iino H, Fujii H and Katoh R: Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum Pathol 43: 834-842, 2012.
40. Jiang N, Reich CF 3rd and Pisetsky DS: Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood 102: 2243-2250, 2003.
41. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ and Anker P: The origin and mechanism of circulating DNA. Ann NY Acad Sci 906: 161-168, 2000.
42. Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437, 2011.
43. Holdenrieder S and Stieber P: Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 46: 1-24, 2009.
44. Stoetzer OJ, Wittwer C, Lehner J, Fahmueller YN, Kohles N, Fersching DM, Leszinski G, Roessner J and Holdenrieder S: Expert Opin Biol Ther Suppl 1: S217-224, 2012.
45. Holdenrieder S, Von Pawel J, Nagel D and Stieber P: Long-term stability of circulating nucleosomes in serum. Anticancer Res 30: 1613-1615, 2010.
46. Deligezer U, Akisik EE, Erten N and Dalay N: Sequencespecific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem 54: 1125-1131, 2008.
47. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837, 2007.
48. Deligezer U, Akisik EZ, Akisik EE, Kovancilar M, Bugra D, Erten N and Dalay N: H3K9me3/H4K20me3 ratio in circulating nucleosomes as potential biomarker for colorectal cancer. In: Circulating Nucleic Acids in Plasma and Serum. Gahan PB (ed.). Springer, Dordrecht, pp. 97-103, 2011.
49. Leszinski G, Gezer U, Siegele B, Stoetzer OJ and Holdenrieder S: Histone modifications H3K9me3 and H4K20me3 on circulating nucleosomes in cancer disease. Anticancer Res 32: 2199-2206, 2012.
50. Gezer U, Ustek D, Yörüker EE, Cakiris A, Abaci N, Leszinski G, Dalay N and Holdenrieder S: Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol 34: 329-336, 2013.
51. Holdenrieder S, Dharuman Y, Standop J, Walgenbach-Brünagel G, Trimpop N, Herzog M, Hettwer K, Simon K, Uhlig S and Micallef J: Novel nucleosomics serum biomarkers for the detection of colorectal cancer. Unpublished data.